Call for Abstract
6th International Conference on Genomics & Pharmacogenomics, will be organized around the theme “Genomic Strategies for Global Health”
Genomics 2016 is comprised of 16 tracks and 130 sessions designed to offer comprehensive sessions that address current issues in Genomics 2016.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Cancer Genomics is the study of genetic mutations responsible for cancer, using genome sequencing and bioinformatics. Clinical genomics is to improve cancer treatment and outcomes lies in determining which sets of genes and gene interactions affect different subsets of cancers. International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers.
- Track 1-1Cancer-related micro RNA and m-RNA
- Track 1-2Tumor Heterogenecity
- Track 1-3Cancer Genomics and Proteomics impact factor
- Track 1-4Molecular underpinnings of therapeutic targets
- Track 1-5Abberant DNA methylation in cancer
- Track 1-6Personal genome screening
- Track 1-7Cancer Genome Analysis
- Track 1-8Cancer Genome Sequencing
- Track 1-9Cancer Genome Alignment
Functional Genomics use vast wealth of data produced by genomic and transcriptomic projectstodescribe gene functions and interactions. Trends in Functional Genomics are Affymetrix emerged as an early innovator in this area by inventing a practical way to analyze gene function as a system. NimbleGen Systems and Febit, are developing fabricated microarrays that are produced using a micro mirror based, mask less system. Texas Instruments developed the micro mirrors that direct light onto specific areas of a grid to activate the DNA synthesis reaction and elongate oligonucleotide chains. BioRobotics, Genetix, Genomic Solutions, and others offer a wide range of products needed to manufacture arrays. Applied Biosystems, PerkinElmer, Qiagen, and Zymark Corporation manufacture automated work stations and robotic systems to fully automate routine laboratory procedures. Invitrogen, PanVera, and Roche Applied Science, have developed complete biochemical and cellular assays that are compatible with high throughput systems Applied Bio systems offers a wide range of core instruments and systems necessary for functional genomics, such as DNA sequencers and synthesizers.
American Society of Transplant Surgeons Up to $100,000 per year ($50,000 in cash and up to $50,000 in-kind) for 2 years. For purposes of this grant, in-kind support is limited to the cost of assays. Genomics Market in the US 2014-2018 and Global Genomics Market 2014-2018 research reports to its store. Functional Genomics market in the US is forecast to grow at a CAGR of 7.28% over the period 2013-2018 whereas the global genomics industry is projected to grow at 11.21% CAGR during the same time. Global genomics market research for 2014-2018 considers the revenue generated by vendors through the sales of instruments, consumables, and services for genomics to arrive at a ranking of the leading vendors of the market, and to calculate the market size.
- Track 2-1Functional genomics and bioinformatics
- Track 2-2CRSPR/CAS9 system for Genome Editing
- Track 2-3Mitochondrial Genomics
- Track 2-4Phytochemical genomics
- Track 2-5Chemical genomics
- Track 2-6Biochemistry, biotechnology, and genomics
- Track 2-7Genomic Sequencing
- Track 2-8Metabolomics
- Track 2-9Microbial functional genomics
- Track 2-10Structural Genomics
- Track 2-11Functional Genomics and Molecular Analysis
- Track 2-12Functional genomics of pain in drug development
- Track 2-13Comparative Functional Genomics
- Track 2-14Patterns and determinants of variation in functional genomics
- Track 2-15Genome Analysis
Next generation sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionized genomic research. The global next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography.
- Track 3-1Exome sequencing
- Track 3-2Hybrid sequencing approach
- Track 3-3Sequencing Technologies
- Track 3-4NGS Data Analysis
- Track 3-5Role of NGS in Cancer Drug Development
- Track 3-6Clinical Applications of NGS
- Track 3-7Advances of NGS in Therapeutics
Biomarker is a measurable indicator of the severity or presence of some disease state.
Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007 and projected to increase to $15 billion in 2010. The accelerating pace of activity in this area is further underlined by a cursory review of the publication space, where the number of relevant scientific articles generated annually has doubled from 20,000 to 40,000 over the past decade. AACR, in partnership with the Food and Drug Administration (FDA) and National Cancer Institute (NCI), formed the AACR-FDA-NCI Cancer Biomarkers Collaborative (CBC) to accelerate the translation of cancer therapeutics into the clinic by shaping the processes for the effective development of validated biomarkers and their use in clinical trials for maximum patient benefit.
- Track 4-1Cancer Biomarkers
- Track 4-2Clinical & Transaltional Biomarkers in Drug Discovery
- Track 4-3Chromosomal Biomarkers of Genomics
- Track 4-4Molecular Imaging Biomarkers
- Track 4-5Bigdata to Advance Personalized Medicine
Pharmacogenomics is the study of the role of genetics in drug response. Computational advances in Pharmacogenomics has proven to be a blessing in research. A large amount of research in the biomedical sciences regarding Pharmacogenomics as of late stems from combinatorial chemistry, genomic mining, omic technologies and high throughput screening. In order for the field to grow rich knowledge enterprises and business must work more closely together and adopt simulation strategies. Major Universities dealing Pharmacogenomics are: Harvard University, US, , University of Cambridge, UK, National University of Singapore, Singapore, University of Oxford, UK, Karolinska Institute, Sweden, Monash University, Australia, Imperial College London, UK, University of Tokyo, Japan, University of Melbourne, Australia, University of Michigan, US.
- Track 5-1Cancer Pharmacogenomics
- Track 5-2Pharmacogenomics
- Track 5-3Molecular diagnostics
- Track 5-4Molecular-targeted interventions including gene therapy
- Track 5-5Biological and small molecule therapeutics
- Track 5-6Biomarker translation and testing
- Track 5-7Toxicogenomics
- Track 5-8Applications of NGS to Pharmacogenomics
- Track 5-9Translational Pharmacogenomics
- Track 5-10Pharmacogenomics in Clinical Therapeutics
- Track 5-11Pharmacogenitics & Individualized therapy
- Track 5-12Nutrigenomics
Clinical Genomics is the use of genome sequencing to inform patient diagnosis and care. The California Initiative to Advance Precision Medicine has just been launched, and it is being headed by UCSF’s high profile recent hire, Atul Butte.
American College of Medical Genetics, formed in 1991 to help improve health through medical genetics, regularly publishes a list of internationally-recognized standards and guidelines describing best practices for testing using genetic approaches. In addition, the International Standards for Cytogenomic Arrays (ISCA) Consortium, of which OGT is a member, is a growing group of molecular genetics laboratories actively working towards improving healthcare through the establishment of guidelines for molecular testing, including the creation of standardized a CGH arrays for clinical genetics research. The Cancer Cytogenomics Microarray Consortium (CCMC) is a similar group, recently founded with the goal of maximizing the benefits provided by microarrays for cancer research. These groups continue to work towards outlining a set of standards to ensure that molecular techniques improve and enhance the services provided by clinical research laboratories.
The global market for Clinical Genomics is expected to reach USD 22.1 billion by 2020, growing at an estimated CAGR of 10.3% from 2014 to 2020, according to a new study by Grand View Research, Inc.
Genomics based personalized medicine segment on the other hand is expected to grow at the fastest CAGR of over 12.0% from 2014 to 2020 due to increasing demand for population based therapeutic solutions and subsequent increase in R&D initiatives. Australian Genome Research Facility (Australia), Baylor College of Medicine Human Genome Sequencing Center (Houston, TX, USA), BC Genome Sciences Centre (BCGSC) – Vancouver, BC, Canada, Beijing Genomics Institute (BGI) – China, Broad Institute of MIT and Harvard – Boston, MA, USA, Cold Spring Harbor Laboratory (CSHL) – Cold Spring Harbor, NY, USA, DOE Joint Genome Institute (JGI) – Walnut Creek, CA, USA, Garvan Institute – Australia, Genome Analysis Center (TGAC) - Norwich, UK, Genome Institute at Washington University (TGI) – St. Louis, MO, USA.
- Track 6-1Gene therapy for cancer treatment
- Track 6-2Techniques and tools in clinical genetics
- Track 6-3Molecular genetics of common and complex diseases
- Track 6-4Clinical gene therapy
- Track 6-5Genomics Healthcare
- Track 6-6Techniques and tools in clinical genetics
- Track 6-7Molecular genetics of common and complex diseases
MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. According to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has established collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection.
- Track 7-1Single Cell MicroRNA Analysis
- Track 7-2PCR analysis of blood and saliva specific microRNA markers
- Track 7-3Ion mobility-mass spectrometry to microRNA analysis
- Track 7-4Single Molecule Genomics
- Track 7-5microRNA expression analysis
- Track 7-6MicroRNA in Cancer
- Track 7-7miRNA expression
- Track 7-8MicroRNA expression
- Track 7-9miRNA Biogenesis
- Track 7-10Meta-analysis of microRNA
- Track 7-11Visual Detection of microRNA
Analysts forecast the Global mRNA market to grow at a CAGR of 13.36 percent over the period 2014-2019. Current trends in mRNA analysis are: RNA sequencing uncovers mechanisms regulating gene expression. The global transcriptomics market was valued at $1,743.2 in 2013. This market is expected to reach $3,773.0 million by 2019 at a CAGR of 13.7% from 2014 to 2019. In this report, the global transcriptomics market is segmented as by technology, by applications, and by end-users. Market by technology comprises of microarray, PCR, sequencing, and RNAi gene silencing technologies whereas, the market by applications include clinical diagnostics, drug discovery, and toxicogenomics. The market by end-users includes pharmaceutical and biotechnology companies, academic research and government institutes, and hospitals and diagnostic centers.
- Track 8-1mRNA expression
- Track 8-2mRNA processing
- Track 8-3mRNA Biomarkers
- Track 8-4Gene expression profiling
- Track 8-5Transcriptome analysis
- Track 8-6Gene fusion analysis
Bioinformatics the science of collecting and analyzing complex biological data such as genetic codes. Molecular medicine requires the integration and analysis of genomic, molecular, cellular, as well as clinical data and it thus offers a remarkable set of challenges to bioinformatics. Bioinformatics nowadays has an essential role both, in deciphering genomic, transcriptomic, and proteomic data generated by high-throughput experimental technologies, and in organizing information gathered from traditional biology and medicine. Research Centers for Bioinformatics are: National Centers for Biomedical Computing, National Center for Simulation of Biological Structures, National Center for the Multiscale Analysis of Genomic and Cellular Networks, National Alliance for Medical Image Computing (NA-MIC), National Center for Biomedical Ontology (NCBO) at Stanford University, Integrate Data for Analysis, Anonymization, and Sharing (IDASH) at the University of California, San Diego. The Canadian government is also ponying up cash for omics research, with the Canada Foundation for Innovation backing several projects as part of a C$30.4 million ($27.6 million) investment in academic research. McGill University scooped the joint-biggest award for a project, C$400,000, to advance its single-cell genomics infrastructure.
- Track 9-1BioData mining
- Track 9-2Computational genomics and computational proteomics
- Track 9-3In vitro models for drug development
- Track 9-4Molecular modelling and drug designing
- Track 9-5Sequence analysis and allignment
- Track 9-6Tools for functional and comparative genomics and proteomics
- Track 9-7Systems genetics and systems biology
First, the vast numbers of species and the much larger size of some genomes makes the entire sequencing of all genomes a non-optimal approach for understanding genome structure. Second, within a given species most individuals are genetically distinct in a number of ways. What does it actually mean, for example, to "sequence a human genome"? The genomes of two individuals who are genetically distinct differ with respect to DNA sequence by definition. These two problems, and the potential for other novel applications, have given rise to new approaches which, taken together, constitute the field of comparative genomics.
- Track 10-1Paleogenomics
- Track 10-2Cancer evolutionary genomics
- Track 10-3Comparative tools for genome assembly
- Track 10-4Genomic Variation
- Track 10-5Gene Annotation
- Track 10-6Gene Order and Phylogenetic reconstruction
- Track 10-7Algorithms for genome evolution
- Track 10-8Gene cluster
- Track 10-9Gene Rearrangement
National Science Foundation (NSF) announces its intention to continue to support plant genome research through the Plant Genome Research Program (PGRP). Plant Genomics Research Program (PGRP) awards from the National Science Foundation (NSF) that NSF offers supplements to support research collaboration with scientist sin developing countries. The intent of Developing Country Collaborations in Plant Genome Research (DCC-PGR) awards is to support collaborative research linking U.S. researchers with partners from developing countries to solve problems of mutual interest in agriculture, energy and the environment, while placing U.S. and international researchers at the center of a global network of scientific excellence.
- Track 11-1Cotton Genome
- Track 11-2Genome evolution and environmental genomics
- Track 11-3Molecular evolution and molecular phylogeny
- Track 11-4Population and quantitative genetics
- Track 11-5Molecular genomics and mendelian inheritance
- Track 11-6Developmental genetics and genomics
- Track 11-7Impact of transposable elements on population diversification and genome evolution
- Track 11-8Comparitive genomics
- Track 11-9Wheat Genome
Genome engineering refers to the strategies and techniques developed in recent years for the targeted, specific modification of the genetic information or genome of living organisms. The CRISPR-cas9 system makes gene editing in many organisms and cells like our own egg, sperm or embryo — more efficient, accessible and simple than ever before. These groundbreaking capabilities have spawned discussions surrounding the ethics and applications of the new system, and have garnered significant attention around the world to ensure ethically correct usage
- Track 12-1Human Genome Engineering
- Track 12-2Multiplex Automated Genomic Engineering
- Track 12-3Induced Pluripotent Stem Cell Technology
- Track 12-4Targeted Genome Editing
- Track 12-5Advances in Genome Editing
- Track 12-6Genome Profiling
- Track 12-7CRISPR/CAS Revolution in Genome Engineering
- Track 12-8Gene Editing using CRISPR/Cas9
- Track 12-9Plant Genome Engineering and Genome Reprogramming
Microbial Genomics- applies recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyze the function and structure of genomes in microbes. Genetics Otago is the largest center for advanced Genetics research in Australia. Focus on 7 main themes, which cover the full spectrum of genetics research. The Centre of Microbial and Plant Genetics (CMPG) was founded in 1953 discoverer of crossing-over sites in chromosomes of meiotic cells. A number of important scientific opportunities exist in genome analysis related to microbiology. Current genome projects, however, do not adequately represent the full range of microorganisms. A microbial genome program based on rational priorities is needed to make strategic decisions about the appropriation and distribution of funding and resources. OpGen filed plans with the U.S. Securities and Exchange Commission to sell 3.75 million shares in an initial public offering with the goal of securing up to $35.2 million. The Gaithersburg, Md.-based microbial genetics analysis company said it will use the money as working capital and to support increased sales and marketing efforts for its genetic tests for multidrug resistance organisms.
- Track 13-1Bacterial and viral Genomics
- Track 13-2Microbiomics
- Track 13-3Microbial functional genomics
- Track 13-4Microbial genetics
- Track 13-5Ecoli Genome and Genomics
Genomics research holds the key to meeting many of the challenges of the coming years. At the moment, the biggest challenge is in data analysis. We can generate large amounts of data very inexpensively, but that overwhelms our capacity to understand it. The major challenge of the Genome Research is we need to infuse genomic information into medical practice, which is really hard. There are issues around confidentiality, education, electronic medical records, how to carry genomic information throughout lifespan and make it available to physicians.
- Track 14-1Genetic epidemiology and pharmacoepidemiology
- Track 14-2Genetic counseling
- Track 14-3Phenomics
- Track 14-4Synthetic biology and bioengineering
- Track 14-5Translational genetics and genomics
- Track 14-6Molecular pharming
- Track 14-7Genomics in ageing
Genomic Medicine as "an emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use." Already, genomic medicine is making an impact in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.
- Track 15-1Biomarkers in Genomic Medicine
- Track 15-2Genomics & epigenomics of disease
- Track 15-3Pharmacogenomics & personalized medicine
- Track 15-4Genomic epidemiology & public health genomics
- Track 15-5Proteomics & metabolomics in medicine
- Track 15-6Systems medicine & informatics
Genomics is the study of the genetic material or genomes of an organism. Analysts forecast the Global Genomics market will grow at a CAGR of 11.21% over the period 2013-2018. According to the report, the most important driver of the market is an increase in the demand for consumables. The growing adoption of genetic testing for various applications, especially in regions such as the APAC, and an increase in genetic testing volumes in North America and Western Europe is increasing the demand for consumables.
- Track 16-1Genomics Asia
- Track 16-2Genomics North America
- Track 16-3Genomics South America
- Track 16-4Genomics Australia
- Track 16-5Genomics Africa
- Track 16-6Genomics Europe